The goal of the existing work was to create matrix transdermal patches with lornoxicam (LXM) gel using lemon oil (LO) and Aloe vera leaves mucilage (AVLM) as penetration enhancers to boost LXM transport crossways the skin and test its in vivo analgesic effects. Nine formulas were produced for this purpose using Design Expert® 11 in line with CCD design. The response factors, on the other hand, were Q1d (Y1), Q2d (Y2) and Q3d, or LXM permeation at days 1, 2 and 3. The AVLM concentration (X1) and lemon oil (X2) were selected as independent variables. The optimized patch's skin sensitivity response and analgesic activity were tested on rats. The results exhibited that a matrix system with prolonged (zero-order) LXM release of 24.15% (@24h), 49.00% (@48h) and 69.45% (optimized for the needed analgesic asset by using AVLM and LO as penetration enhancers. It was resolute that the formulation known as LTDP-8, which contains 3mL of AVLM and LO as permeability enhancers, is the best one. In light of its ability to administer LXM across the skin sustainably while producing a tolerable analgesic effect. The study concludes that the artificial transdermal LXM delivery system is a suitable substitution for the oral route.